Phase IIb trial of nitric oxide-donating prostaglandin F2 alpha analog reduces IOP in glaucoma

Positive phase IIb clinical trial data has supported the continuing development of a nitric oxide (NO)-donating prostaglandin F2-alpha analog for the treatment of primary open-angle glaucoma and ocular hypertension. The randomized investigator-masked phase IIb study has demonstrated that a once daily treatment met the study’s primary end-point of reducing the mean diurnal intracocular pressure (IOP) from baseline at day 28 (versus 0.005% latanaprost). A phase III study will now be scheduled to begin at the end of 2012 or early 2013.